Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 20/20 | 0.51 |
| ▸ | TCF7L2 | Q9NQB0 | 20/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL940842 | 0.90 | FLT3 (0.47) | CTNNB1TCF7L2 | |
| SCHEMBL940614 | 0.86 | ALDH1A1 (0.44) | — | |
| SCHEMBL5787889 | 0.85 | MEN1 (0.39) | CTNNB1TCF7L2 | |
| SCHEMBL941803 | 0.82 | ADORA2A (0.43) | CTNNB1TCF7L2 | |
| SCHEMBL940906 | 0.81 | ADORA2A (0.43) | CTNNB1TCF7L2 | |
| SCHEMBL940803 | 0.78 | ADORA2A (0.41) | — | |
| SCHEMBL940004 | 0.78 | ALDH1A1 (0.42) | — | |
| SCHEMBL2012739 | 0.78 | ADORA2A (0.47) | CTNNB1TCF7L2 | |
| SCHEMBL939862 | 0.78 | ADORA2A (0.47) | CTNNB1TCF7L2 | |
| SCHEMBL939909 | 0.77 | CTNNB1 (0.49) | CTNNB1TCF7L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8071601-B2 | Aminoquinoline derivatives and their use as adenosine A3 ligands | SANOFI-AVENTIS (FR) | 2011-12-06 | — | — | US | claimed |
| US-20110112092-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-AVENTIS (FR) | 2011-05-12 | — | — | US | claimed |
| CN-100402501-C | Aminoquinoline derivatives and their use as adenosine A3Use of ligands | SANOFI AVENTIS (FR) | 2008-07-16 | — | — | CN | claimed |
| EP-1663982-B1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI AVENTIS (FR) | 2007-11-21 | — | — | EP | claimed |
| US-20060211689-A1 | Aminoquinoline derivatives and their use as adenosine A3 ligands | SANOFI-AVENTIS U.S. LLC (US) | 2006-09-21 | — | — | US | claimed |
| CN-1829695-A | Aminoquinoline derivatives and their use as adenosine A3Use of ligands | SANOFI AVENTIS (FR) | 2006-09-06 | — | — | CN | claimed |
| US-8071601-B2 | Aminoquinoline derivatives and their use as adenosine A3 ligands | SANOFI-AVENTIS (FR) | 2011-12-06 | — | — | US | disclosed |
| US-20110112092-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-AVENTIS (FR) | 2011-05-12 | — | — | US | disclosed |
| CN-101239945-B | Aminoquinoline derivatives and their use as adenosine a3 ligands | SANOFI AVENTIS | 2011-04-13 | — | — | CN | disclosed |
| US-20110009626-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
| US-7799922-B2 | Aminoquinoline derivatives and their use as adenosine A3 ligands | SANOFI-AVENTIS (FR) | 2010-09-21 | — | — | US | disclosed |
| US-20090247745-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI-AVENTIS (FR) | 2009-10-01 | — | — | US | disclosed |
| US-7547696-B2 | Such as 4-methoxy-N-[6-(morpholin-4-yl)-4-benzylamino-3-cyanoquinolin-2-yl]-benzamide; improved solubility | SANOFI-AVENTIS (FR) | 2009-06-16 | — | — | US | disclosed |
| CN-101239945-A | Aminoquinoline derivatives and their use as adenosine a3 ligands | SANOFI AVENTIS (FR) | 2008-08-13 | — | — | CN | disclosed |
| CN-100402501-C | Aminoquinoline derivatives and their use as adenosine A3Use of ligands | SANOFI AVENTIS (FR) | 2008-07-16 | — | — | CN | disclosed |
| EP-1663982-B1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | SANOFI AVENTIS (FR) | 2007-11-21 | — | — | EP | disclosed |
| US-20060211689-A1 | Aminoquinoline derivatives and their use as adenosine A3 ligands | SANOFI-AVENTIS U.S. LLC (US) | 2006-09-21 | — | — | US | disclosed |
| CN-1829695-A | Aminoquinoline derivatives and their use as adenosine A3Use of ligands | SANOFI AVENTIS (FR) | 2006-09-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211689-A1 | Aminoquinoline derivatives and their use as adenosine A3 ligands | ADORA3, ADORA2A, ADORA1 | CTNNB1 230/4885TCF7L2 1467/4885 |
| US-20090247745-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | ADORA3, ADORA2A, ADORA1 | CTNNB1 230/4885TCF7L2 1467/4885 |
| US-20110112092-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | ADORA3, ADORA2A, ADORA2B | CTNNB1 2571/4885TCF7L2 3173/4885 |
| US-20110009626-A1 | AMINOQUINOLINE DERIVATIVES AND THEIR USE AS ADENOSINE A3 LIGANDS | ADORA3, ADORA2A, ADORA2B | CTNNB1 2347/4885TCF7L2 2413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.